Faidon-Marios Laskaratos1, Joseph Davar2, Christos Toumpanakis3. 1. Neuroendocrine Tumour Unit, Centre for Gastroenterology, Royal Free Hospital, London, UK. 2. Carcinoid Heart Disease Clinic, Royal Free Hospital, London, UK. 3. Neuroendocrine Tumour Unit, Centre for Gastroenterology, Royal Free Hospital, London, UK. c.toumpanakis@ucl.ac.uk.
Abstract
PURPOSE OF REVIEW: The development of carcinoid heart disease (CHD) is a fibrotic complication of neuroendocrine neoplasms (NEN) which is associated with a poor prognosis. This review aims to summarise the clinical features, investigations and management of this condition. RECENT FINDINGS: CHD can affect up to 50% of NET patients with carcinoid syndrome. However, it is often not screened for appropriately and recognised late when patients become symptomatic. A screening strategy with biomarkers and multimodality imaging is necessary for early recognition. Management by an experienced multidisciplinary team with appropriate medical therapeutic strategies and where indicated surgical intervention is needed to optimise clinical outcomes. CHD is a poor prognostic factor, but recently, outcomes have improved due to the multidisciplinary approach and centralised care of CHD-NET patients.
PURPOSE OF REVIEW: The development of carcinoid heart disease (CHD) is a fibrotic complication of neuroendocrine neoplasms (NEN) which is associated with a poor prognosis. This review aims to summarise the clinical features, investigations and management of this condition. RECENT FINDINGS: CHD can affect up to 50% of NET patients with carcinoid syndrome. However, it is often not screened for appropriately and recognised late when patients become symptomatic. A screening strategy with biomarkers and multimodality imaging is necessary for early recognition. Management by an experienced multidisciplinary team with appropriate medical therapeutic strategies and where indicated surgical intervention is needed to optimise clinical outcomes. CHD is a poor prognostic factor, but recently, outcomes have improved due to the multidisciplinary approach and centralised care of CHD-NET patients.
Authors: H M Connolly; J L Crary; M D McGoon; D D Hensrud; B S Edwards; W D Edwards; H V Schaff Journal: N Engl J Med Date: 1997-08-28 Impact factor: 91.245
Authors: Judit Horvath; Robin D Fross; Galit Kleiner-Fisman; René Lerch; Hans Stalder; Suzanne Liaudat; William J Raskoff; Keith D Flachsbart; Harry Rakowski; Jean-Claude Pache; Pierre R Burkhard; Anthony E Lang Journal: Mov Disord Date: 2004-06 Impact factor: 10.338
Authors: Simona Grozinsky-Glasberg; Joseph Davar; Johannes Hofland; Rebecca Dobson; Vikas Prasad; Andreas Pascher; Timm Denecke; Margot E T Tesselaar; Francesco Panzuto; Anders Albåge; Heidi M Connolly; Jean-Francois Obadia; Rachel Riechelmann; Christos Toumpanakis Journal: J Neuroendocrinol Date: 2022-05-25 Impact factor: 3.870